Last reviewed · How we verify

Dexketoprofen Trometamol

Tokat Gaziosmanpasa University · FDA-approved active Small molecule

Dexketoprofen trometamol is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Dexketoprofen trometamol is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Acute pain (postoperative, dental, musculoskeletal), Rheumatoid arthritis, Osteoarthritis.

At a glance

Generic nameDexketoprofen Trometamol
Also known asArveles 25 mg 20 tablets, Revafen(Dexketoprofen Trometamol), Enantyum, Miracox, arveles
SponsorTokat Gaziosmanpasa University
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaPain Management, Rheumatology, Inflammation
PhaseFDA-approved

Mechanism of action

As the active S-enantiomer of ketoprofen complexed with trometamol (tromethamine), dexketoprofen trometamol selectively inhibits COX-1 and COX-2 enzymes. This inhibition reduces prostaglandin production, which mediates inflammatory responses and pain signaling. The trometamol salt formulation enhances solubility and provides faster onset of action compared to standard ketoprofen.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: